• Harlan M Krumholz.
• Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA.
• Yonsei Med. J. 2022 May 1; 63 (5): 493-498.

AbstractWe are now on the cusp of massive adoption of digital health technologies. Medicine is becoming an information science intertwined with technology and data science. This talk aims to describe the current state of digital transformation in healthcare, to identify reasons for enthusiasm and caution, and to provide a framework for thinking about what is necessary for hospitals and health systems to be confident about incorporating these innovations into practice. I have three key recommendations. First, we should buy results, not claims. Those in positions that influence decisions about endorsing or purchasing digital products designed to improve care or outcomes ought to buy results, not claims or intermediate results. Moreover, although analytic validity and clinical validity are important, they sometimes do not reflect the impact of a product in its entirety. Ultimately, we need to know whether patients benefit. Second, we should insist on transparency. The performance of a product cannot be a secret. The basis on which developers make claims about their products should be open to all, including patients. Better yet, data on which experts reach a conclusion should be shared, just as many companies share research data on drugs and devices. Third, we should be aware of unintended adverse consequences. We should evaluate every intervention for unintended adverse consequences. Changes to systems, with all good intentions, can always go awry. In conclusion, insistence on good and evolving evidence is the best way to arrive at our destination: the use of innovations to improve outcomes.© Copyright: Yonsei University College of Medicine 2022.

6 keywords...

hide…